Stay up to date with rheumatology news & updates by subscribing to receive the free RPM print publications or e‑Newsletters.
According to the results of 2 separate clinical trials presented at the 2018 Genitourinary Cancers Symposium, apalutamide and enzalutamide reduced the risk for metastasis and prolonged metastasis-free survival in patients with nonmetastatic castrate-resistant prostate cancer.
Scott Gottlieb was recently confirmed as FDA Commissioner. It is believed that he would be able to swiftly execute changes that could help to accelerate drug approvals and lower drug prices to meet Trump’s goals.
“This study’s findings—that adding antiandrogen therapy to the radiation typically used against recurrence reduces the incidence of metastasis, death from prostate cancer and overall deaths—will change the standard of care for patients experiencing a postoperative recurrence,” Dr Shipley added.
Read Now